RBC Capital analyst Sean Dodge raised the firm’s price target on R1 RCM to $18 from $14 and keeps an Outperform rating on the shares ahead of its Q4 results. Publicized hiccups during the Pediatrix/LifePoint implementations have weighed heavily on shares, and are likely keeping new investors sidelined until there’s more evidence these issues are resolved, the analyst tells investors in a research note. The firm adds however that R1 RCM continues to be its favorite idea on "high" conviction in a 3-year mid/high-teens EBITDA CAGR outlook.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RCM:
- Truist downgrades ‘show me story’ R1 RCM to Hold
- R1 RCM price target raised to $20 from $15 at KeyBanc
- R1 RCM downgraded to Hold from Buy at Truist
- R1 RCM to Release Fourth Quarter 2022 Results on February 16
- R1 RCM Announces Leadership Appointments; Reaffirms 2022 Guidance and Announces 2023 Outlook